



## Personalized Medicine: (A Comprehensive Review)

**AKASH PANDEY and SURYA PRAKASH GUPTA\***

Rajiv Gandhi Institute of Pharmacy Faculty of Pharmaceutical Science  
& Technology AKS University, Satna-485001, (MP), India.

\*Corresponding author Email: suryatony@yahoo.co.in

<http://dx.doi.org/10.13005/ojc/400403>

(Received: May 09, 2024; Accepted: July 13, 2024)

### ABSTRACT

Personalized medicine, also known as precision medicine, represents a revolutionary approach to healthcare, tailoring medical interventions to individuals based on their unique characteristics such as genetics, environment, and lifestyle. This shift from a one-size-fits-all model to a targeted approach holds great promise for enhancing patient outcomes, improving treatment effectiveness, and reducing adverse effects. Advancements in genomics, proteomics, and data analysis have facilitated the identification of biomarkers and treatment targets, leading to the development of personalized diagnostics and therapies across various medical fields. However, the widespread adoption of personalized medicine is hindered by challenges like data privacy, regulatory obstacles, and ensuring equal access to innovative technologies. This summary outlines the principles, technological progress, clinical applications, obstacles, and future prospects of personalized medicine, underscoring its potential to transform healthcare delivery and introduce a new era of precision medicine. Personalized medicine represents a healthcare model incorporating periodic, individualized, participatory, and predictive measures. It aims to improve treatment outcomes by pinpointing the genetic factors underlying an individual's illness. Personalized medicine holds promise for decreasing both financial and time costs while enhancing patients' quality of life and potentially extending their life spans. It represents an approach to improve treatment outcomes by identifying the genomic makeup responsible for causing diseases in individuals. Personalized medicine encompasses a wide range of applications and can be utilized for diagnosing various illnesses.

**Keywords:** Personalized medicine, Genome, Diagnosis, Target therapy, individual's illness.

### INTRODUCTION

Personalized medicine signifies a transformative shift in healthcare, marking a departure from standardized approaches towards individualized treatments. It acknowledges the significance of genetic makeup, lifestyle, and environmental factors in health and treatment response<sup>1</sup>. Utilizing advanced technologies such as

genomics and data analytics, personalized medicine aims to innovate healthcare delivery by offering precise and targeted therapies.

At its core, personalized medicine relies on a thorough examination of an individual's genetic composition through genomic sequencing. This allows healthcare professionals to pinpoint specific genetic variations and mutations impacting disease



susceptibility, drug metabolism, and treatment response<sup>2</sup>. Armed with this knowledge, clinicians can customize treatment strategies to align with each patient's distinct genetic profile, optimizing effectiveness and minimizing adverse reactions.

The vision for personalized medicine in the 21<sup>st</sup> century is centered around delivering the correct medication, at the appropriate dosage, and precisely timed for each individual patient<sup>3</sup>. The successful implementation of personalized medicine depends significantly on the existence of robust diagnostic tools that enable the selection of the most suitable therapeutic product to enhance patient outcomes. These products undergo thorough regulation by both manufacturers and the Food and Drug Administration<sup>4</sup>.

Personalized medicine holds potential across various dimensions of healthcare. It enhances diagnostic accuracy by pinpointing genetic markers linked to specific illnesses, thereby enabling earlier intervention and improved outcomes. Additionally, it streamlines treatment selection tailored to individual patients, maximizing therapeutic effectiveness and enhancing patient satisfaction<sup>5</sup>.

Furthermore, personalized medicine empowers preventive healthcare by identifying genetic predispositions and risk factors, facilitating targeted prevention strategies. This proactive approach not only lowers disease incidence but also promotes overall well-being and longevity. A fundamental aspect of personalized medicine is genomic sequencing, enabling thorough analysis of an individual's genetic blueprint. By identifying genetic variations and mutations linked to disease risk, drug metabolism, and treatment response, healthcare providers can customize interventions according to each patient's genetic profile.

This individualized method shows great potential in numerous aspects of healthcare:

✓ **Precision Diagnosis:** Through the identification of genetic markers and molecular patterns linked to particular diseases, personalized medicine allows for earlier and more precise diagnosis, resulting in more focused and efficient treatments<sup>6</sup>.

✓ **Customized Treatment:** Personalized medicine enables the selection of treatments tailored to the individual's likelihood of effectiveness, while reducing the chances of adverse reactions or treatment resistance. This can lead to enhanced outcomes and a better quality of life for patients<sup>7</sup>.

✓ **Preventive Care:** By evaluating an individual's genetic predispositions and risk factors, personalized medicine facilitates the formulation of personalized prevention plans. This encompasses lifestyle adjustments, screening strategies, and early interventions to mitigate disease risk and promote well-being<sup>8</sup>.

✓ **Clinical Research:** Personalized medicine is fostering innovation in clinical research, facilitating the creation of new therapies and interventions targeting specific genetic variations or molecular pathways. This strategy has the potential to expedite medical discoveries and expedite the introduction of novel treatments to the market<sup>9</sup>.

While personalized medicine has made significant progress recently, challenges persist regarding access to genetic testing, concerns about data privacy, and the integration of personalized medicine into everyday clinical practice. However, with ongoing technological advancements and increasing awareness among healthcare professionals and patients, personalized medicine stands ready to transform healthcare delivery and enhance patient outcomes worldwide.

Personalized medicine is an emerging medical practice that utilizes an individual's genetic information to inform decisions related to disease prevention, diagnosis, and treatment. Understanding a patient's genetic makeup assists physicians in selecting the appropriate medication or therapy and administering it at the correct dosage or schedule. The advancement of personalized medicine is propelled by data from initiatives such as the Human Genome Project<sup>10</sup>.

Different stakeholders in healthcare, including physicians, healthcare administrators, insurers, and ultimately, patients, play a role in the implementation of personalized medicine<sup>11</sup>.

### What is personalized medicine

Personalized medicine, also known as precision medicine, is an approach to medical treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Instead of the traditional one-size-fits-all approach, personalized medicine aims to tailor medical care and interventions to the specific characteristics of each patient<sup>12</sup>.

### Here's how it works

- ✓ **Genetic Information:** Personalized medicine often involves analyzing a person's genetic makeup to understand how their genes influence their health, disease risk, and response to treatments. This might involve genetic testing to identify variations in genes that may predispose someone to certain diseases or affect their response to medications<sup>13</sup>.
- ✓ **Tailored Treatment Plans:** Based on this genetic information and other factors such as environmental exposures and lifestyle choices, healthcare providers can develop personalized treatment plans that are more effective and potentially safer than generic treatments<sup>14</sup>. For example, certain cancer therapies can be targeted to specific genetic mutations present in a patient's tumor, leading to better outcomes and fewer side effects.
- ✓ **Preventive Strategies:** Personalized medicine also emphasizes preventive strategies based on an individual's unique risk factors. By identifying genetic predispositions to certain diseases or lifestyle factors that may increase risk, healthcare providers can recommend personalized interventions to reduce the likelihood of developing these conditions<sup>15</sup>.
- ✓ **Monitoring and Adjustment:** Personalized medicine may involve ongoing monitoring of a patient's health and treatment response to adjust as needed. This could include regular genetic testing, monitoring of biomarkers, or other diagnostic tests to assess how well a treatment is working and whether any modifications are necessary<sup>16</sup>.

Overall, personalized medicine has the potential to revolutionize healthcare by providing

more precise and effective treatments, improving patient outcomes, and reducing healthcare costs by avoiding ineffective or unnecessary interventions. However, challenges remain in terms of access to genetic testing, data privacy concerns, and ensuring that healthcare providers have the necessary training and resources to implement personalized medicine approaches effectively.

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual's medical history, circumstances, and values, health care providers can develop targeted prevention and treatment plans with their patients<sup>12</sup>. Personalized medicine is the tailoring of medical treatment to the individual characteristics of each patient. The approach relies on scientific breakthroughs in our understanding of how a person's unique molecular and genetic profile makes them susceptible to certain diseases. This same research is increasing our ability to predict which medical treatments will be safe and effective for each patient, and which one will not be. Personalized medicine may be considered an extension of traditional approaches to understanding and treating disease. Equipped with tools that are more precise, physicians can select a therapy or treatment protocol based on a patient's molecular profile that may not only minimize harmful side effects and ensure a more successful outcome, but can also help contain costs compared with a "trial-and-error" approach to disease treatment<sup>17</sup>. Personalized medicine has the potential to change the way we think about, identify and manage health problems. It is already having an exciting impact on both clinical research and patient care, and this impact will grow as our understanding and technologies improve<sup>18</sup>.

### Challenge view of personalized

A challenge view of Personalized medicine is acknowledged as an innovative addition to the healthcare system, characterized by its focus on prevention, coordination, and demonstrated effectiveness<sup>19,20</sup>. Despite its potential, stakeholders and consumers have yet to fully appreciate the advantages of personalized medicine within the existing healthcare framework. Recent research

highlights several hurdles impeding the progress of personalized medicine, encompassing scientific challenges-such as determining the clinical significance of genetic markers and gaps in understanding the molecular mechanisms of specific diseases<sup>21</sup>. Economic obstacles also arise, alongside operational complexities in identifying technologies and operational systems that yield cost savings<sup>22</sup>. Moreover, concerns persist regarding safeguarding private information during the investigative and developmental phases. Policy-related dilemmas further complicate matters, particularly concerning the collaboration between government research bodies and regulatory authorities<sup>23</sup>.

While personalized medicine holds great promise in tailoring treatments to individual patients based on their unique genetic makeup, lifestyle factors, and environment, several challenges must be addressed:

- ✓ **Data Privacy and Security:** Personalized medicine relies heavily on collecting and analyzing sensitive patient data, including genetic information. Ensuring the privacy and security of this data is crucial to maintaining patient trust and compliance<sup>24</sup>.
- ✓ **Cost:** Developing personalized treatments can be expensive, involving complex diagnostic tests, genetic sequencing, and specialized therapies. Access to these treatments may be limited by cost, particularly for individuals without adequate insurance coverage<sup>25</sup>.
- ✓ **Ethical Concerns:** Personalized medicine raises ethical questions regarding the use of genetic information for decision-making, potential discrimination based on genetic predispositions, and the equitable distribution of resources<sup>26</sup>.
- ✓ **Regulatory Hurdles:** Regulatory agencies face the challenge of establishing guidelines for the approval and oversight of personalized treatments, balancing the need for innovation with patient safety and efficacy<sup>27</sup>.
- ✓ **Interdisciplinary Collaboration:** Successful implementation of personalized medicine requires collaboration among healthcare providers, researchers, policymakers, and technology experts. Bridging the gap between these disciplines can be challenging but is essential for progress in the field<sup>28</sup>.

- ✓ **Health Inequities:** There is a risk that personalized medicine could exacerbate existing health inequities if access to cutting-edge treatments is disproportionately available to certain populations or regions<sup>29</sup>.
- ✓ **Data Interpretation:** Analyzing and interpreting the vast amount of data generated in personalized medicine poses a significant challenge. Integrating genetic, clinical, and environmental data to make actionable treatment recommendations requires advanced computational and analytical techniques<sup>30</sup>.
- ✓ **Patient Education and Engagement:** Empowering patients to make informed decisions about personalized treatments requires education about the benefits, risks, and limitations of genetic testing and tailored therapies<sup>31</sup>.

Addressing these challenges will be essential for realizing the full potential of personalized medicine and ensuring that its benefits patients across diverse populations. Collaboration, innovation, and a commitment to ethical principles are key to overcoming these obstacles and advancing the field of personalized medicine.

#### How does personalized medicine help patients?

Personalized medicine can involve preventive, diagnostic, or treatment strategies.

#### Prevention

Preventive personalized medicine is designed to help patients understand their molecular and environmental disease risks.

#### Diagnosis

Diagnostic tests can uncover the root molecular causes of certain diseases. The results may point to a promising targeted treatment option that would otherwise be overlooked<sup>32</sup>.

#### Treatment

Personalized medicines can address the root molecular causes of certain diseases. For many patients, molecularly targeted treatment regimens are safer and more effective than one-size-fits-all options<sup>18</sup>.




Fig. 1. Personalized medicine help patients

- ✓ **Targeted Treatments:** Personalized medicine uses genetic, environmental, and lifestyle factors to identify the most effective treatment for a particular individual. This means treatments are more likely to be effective because they're specifically chosen based on the patient's unique biological makeup.
- ✓ **Reduced Adverse Effects:** By considering individual variations, personalized medicine aims to minimize adverse effects. Medications and therapies are chosen with a better understanding of how a patient's body will respond, reducing the likelihood of harmful side effects.
- ✓ **Improved Outcomes:** By targeting treatments more precisely, personalized medicine often leads to improved patient outcomes. This can mean better disease management, increased survival rates, and improved quality of life for patients.
- ✓ **Early Detection and Prevention:** Personalized medicine utilizes genetic testing and other advanced diagnostic tools to detect diseases earlier and identify individuals who are at a higher risk of developing certain conditions. This enables proactive interventions and preventive measures to be implemented, potentially avoiding or delaying the onset of disease.
- ✓ **Tailored Dosages:** Personalized medicine may also involve customizing medication dosages based on factors such as genetic variations, metabolism rates, and other individual characteristics. This can optimize treatment efficacy while minimizing the risk of under or overdosing.
- ✓ **Cost-Effectiveness:** Although personalized medicine often involves advanced diagnostic techniques and treatments, it can ultimately be cost-effective by avoiding unnecessary treatments, reducing hospitalizations, and improving overall healthcare efficiency<sup>33</sup>.

### Innovations in personalized medicine

The FDA is actively involved in the creation and evaluation of animal models to assess the safety and efficacy of bacteriophage cocktails for treating bacterial infections classified as resistant to antibacterial agents. Other advancements include the development and application of gene therapies and pharmacogenetic tests. These tests provide clinicians with insights into how an individual's genetic composition affects their response to specific treatments. Additionally, FDA researchers are investigating crucial regulatory science questions related to drug approval, particularly regarding the use of immunotherapy agents and novel treatments for various cancers. They are also exploring the role of genetics in the development of immune-related adverse effects and the response to such agents<sup>34</sup>. In January 2021, the FDA announced its actions in providing clinicians with information on the development of novel therapies as the role of personalized medicine continues to expand. The FDA issued a draft guidance on submissions for investigational new drugs for individualized antisense oligonucleotide (ASO) agents that are intended to treat a severely debilitating or life-threatening genetic disease<sup>31,35</sup>. The guidance was established to instruct those sponsors developing ASO products on a methodology to interacting with and making regulatory submissions to the FDA. The guidance addresses the following points<sup>31,35</sup>. The method to obtaining response from the FDA with an established communication plan; the expectations and procedure for creating regulatory submissions to the FDA; and recommendations about the condition for Institutional Review Board review of the protocols within and how to acquire informed consent.

### Application of personalized medicine

Here are several key applications of personalized medicine:

1. Identifying diseases at earlier stages of development through optimized surveillance, allowing for more effective interventions or treatment options.
2. Minimizing preventable complications and side effects associated with drug use by avoiding generic "one size fits all" prescribing practices.
3. Optimizing therapeutic effectiveness by ensuring the appropriate drug is administered and considering any genetic variations that may impact drug metabolism when determining dosing regimens.
4. Supporting individuals at elevated risk of developing diseases by promoting and assisting with adherence to available prevention strategies.
5. **Genetic Testing:** Genetic tests can identify inherited predispositions to certain diseases, allowing for early intervention or preventive measures. For example, BRCA gene testing can determine the risk of developing breast and ovarian cancer, enabling personalized screening and treatment plans<sup>36</sup>.
6. **Cancer Treatment:** Personalized medicine in oncology involves analyzing the genetic makeup of tumors to identify specific mutations driving cancer growth. This information helps oncologists select targeted therapies that are more effective and have fewer side effects compared to traditional chemotherapy<sup>37</sup>.
7. **Pharmacogenomics:** Pharmacogenomic testing examines how an individual's genetic makeup influences their response to drugs. This information can guide healthcare providers in prescribing the most suitable medications and dosages, minimizing adverse reactions and optimizing treatment efficacy<sup>38</sup>.
8. **Infectious Disease Management:** Personalized medicine is increasingly being applied in the treatment of infectious diseases, such as HIV and hepatitis C. Genetic testing helps determine the most effective antiviral medications for individual patients, taking into account factors like drug resistance mutations and host genetics<sup>39</sup>.
9. **Rare Diseases:** Personalized medicine offers hope for individuals with rare genetic disorders by providing targeted therapies tailored to their specific genetic mutations. This approach can improve treatment outcomes and quality of life for patients with conditions that have limited therapeutic options<sup>40</sup>.
10. **Preventive Medicine:** By analyzing an individual's genetic predisposition to certain diseases, personalized medicine enables proactive preventive measures<sup>41</sup>. This may include lifestyle modifications, tailored screening programs, and early interventions to reduce the risk of developing chronic illnesses such as cardiovascular disease and diabetes.
11. **Patient Stratification in Clinical Trials:** Personalized medicine enhances the efficiency of clinical trials by identifying patient subgroups most likely to benefit from experimental treatments. This approach facilitates the development of novel therapies with greater efficacy and safety profiles, leading to more successful clinical outcomes<sup>42</sup>.
12. **Behavioral Health and Psychiatry:** Genetic testing and personalized medicine approaches are increasingly being explored in psychiatry and behavioral health to optimize the selection of psychotropic medications and improve treatment outcomes for conditions like depression, anxiety, and schizophrenia<sup>43</sup>.

Overall, personalized medicine holds the promise of delivering more precise, effective, and patient-centered healthcare across a wide range of medical specialties, ultimately leading to better clinical outcomes and improved quality of life for patients.

#### Benefits of personalized medicine

- Providing advantages to healthcare systems and society.
- Enhancing patient treatments.
- Streamlining the development of new medications<sup>44</sup>.
- Enhance the detection of diseases.
- Decrease the duration, expenses, and rate of failure in pharmaceutical clinical trials.
- Eradicate the inefficiencies of trial-and-error approaches that inflate healthcare expenses and compromise patient care<sup>45</sup>.

- **Tailored Treatments:** Personalized medicine allows healthcare providers to tailor treatments to individual patients based on their genetic makeup, lifestyle factors, and specific disease characteristics. This customization increases the likelihood of treatment success while minimizing adverse effects<sup>46,47</sup>.
  - **Improved Outcomes:** By targeting treatments to the specific molecular mechanisms driving a patient's disease, personalized medicine can lead to improved clinical outcomes. This can include better disease management, reduced recurrence rates, and increased survival rates<sup>48</sup>.
  - **Optimized Drug Selection:** Genetic testing and molecular profiling enable healthcare providers to identify which drugs are most likely to be effective for a particular patient, avoiding trial-and-error approaches and reducing the risk of adverse drug reactions<sup>49</sup>.
  - **Prevention and Early Detection:** Personalized medicine emphasizes proactive approaches to healthcare, including genetic screening for predispositions to certain diseases and the early detection of conditions based on individual risk profiles<sup>50</sup>. This can facilitate early interventions and preventive measures to mitigate disease progression.
  - **Healthcare Cost Savings:** Although personalized medicine may initially involve higher upfront costs for genetic testing and diagnostics, it can lead to long-term healthcare cost savings by reducing hospitalizations, complications, and ineffective treatments<sup>51</sup>. This can create opportunities for value-based partnerships with healthcare payers and providers.
  - **Reduced Development Costs:** By identifying patient subpopulations most likely to benefit from a drug during clinical trials, personalized medicine can streamline drug development processes and reduce overall costs. This targeted approach increases the probability of success in clinical trials and reduces the likelihood of late-stage trial failures<sup>52</sup>.
  - **Extended Patent Lifespan:** Drugs developed through personalized medicine approaches may qualify for extended patent protection if they target specific genetic mutations or biomarkers<sup>53</sup>. This exclusivity can provide pharmaceutical companies with additional time to recoup research and development investments and generate profits.
  - **Patient Empowerment:** Personalized medicine empowers patients by involving them in decision-making processes regarding their healthcare. By understanding their genetic risks and treatment options, patients can make informed choices that align with their values and preferences<sup>54</sup>.
  - **Advancements in Research and Drug Development:** Personalized medicine generates vast amounts of data on genetic variations, disease pathways, and treatment responses, which can inform future research and drug development efforts<sup>55</sup>. This facilitates the development of more targeted therapies and enhances our understanding of complex diseases.
  - **Brand Loyalty and Competitive Advantage:** Companies that pioneer personalized medicine approaches can establish themselves as leaders in the field and build strong brand loyalty among healthcare providers and patients. This competitive advantage can translate into long-term profitability and market dominance<sup>56</sup>.
- Personalized medicine has the capability to enhance drug choice and precision therapy, lessen adverse reactions, enhance patient adherence, transition medicine from a reactive to a preventative approach, enhance cost efficiency, and bolster patient trust post-launch by endorsing innovative treatment approaches and reshaping medicine's role within the healthcare framework<sup>57</sup>.
- The role of the pharmacist**
- Pharmacists play a crucial role in personalized medicine by bridging the gap between healthcare providers, patients, and personalized treatment plans. Here's how pharmacists contribute:
- ✓ **Medication Management:** Pharmacists are experts in medication management. In personalized medicine, they help ensure that medications prescribed are tailored to the individual patient's genetic makeup, medical history, and other relevant factors. They may adjust dosages, select appropriate formulations, and monitor medication responses<sup>58</sup>.

- ✓ **Genetic Counseling:** Pharmacists may provide genetic counseling services to patients undergoing genetic testing as part of personalized medicine. They help patients understand the implications of genetic test results, including potential medication interactions, risks, and benefits<sup>59</sup>.
- ✓ **Interpretation of Genetic Data:** Pharmacists have the expertise to interpret genetic data and apply it to medication selection and dosing decisions. They work closely with healthcare providers to incorporate genetic information into treatment plans effectively.
- ✓ **Adverse Drug Reaction Management:** Pharmacists are trained to recognize and manage adverse drug reactions. In personalized medicine, they play a crucial role in identifying and mitigating adverse reactions that may arise due to genetic variations or other individual factors<sup>60</sup>.
- ✓ **Patient Education and Counseling:** Pharmacists educate patients about their medications, including how they work, potential side effects, and the importance of adherence<sup>61</sup>. In personalized medicine, they provide tailored education to help patients understand how their genetic makeup influences their response to treatment.
- ✓ **Collaboration with Healthcare Team:** Pharmacists collaborate with other healthcare providers, including physicians, genetic counselors, and other specialists, to develop comprehensive personalized treatment plans for patients<sup>62</sup>. They contribute their expertise in medication management to ensure that treatments are safe, effective, and well-integrated with other aspects of patient care.
- ✓ **Research and Development:** Pharmacists may also be involved in research and development efforts related to personalized medicine, including the development of pharmacogenomic tests, novel drug therapies, and innovative approaches to medication management<sup>63</sup>.

As personalized medicine becomes increasingly integrated into clinical settings, it's crucial for pharmacists to stay informed about advancements in its potential applications in diagnosing, treating, and preventing specific diseases, as well as recent approvals and ongoing

research. Literature suggests that pharmacists, leveraging their expertise in drug pharmacokinetics and pharmacodynamics, can play a vital role in raising awareness about pharmacogenomics and personalized medicine<sup>64</sup>. For instance, the American Society of Health-System Pharmacists (ASHP) suggests that pharmacogenomic testing has the potential to enhance medication-related outcomes across various healthcare settings.

ASHP mentions that advantages could involve a decrease in less-than-ideal clinical results, lowered treatment expenses, improved medication adherence, better selection of therapeutic agents, shortened treatment duration, and increased patient safety due to pharmacist involvement. Furthermore, leveraging their expertise, pharmacists can play a crucial role in collaborating with clinicians to ensure the ideal selection and dosing of drugs based on pharmacogenomic testing outcomes<sup>65</sup>. In general, pharmacists fulfill a diverse role in personalized medicine, utilizing their knowledge in medication management, genetics, and patient care to enhance treatment results tailored to each patient.

#### **Is personalized medicine truly personalized**

Many individuals might assume that personalized medicine exclusively focuses on individualized care due to its name. However, while the Wikipedia definition emphasizes patient-specific approaches, the President's Council explicitly mentions subpopulations rather than individual patients. In contrast, the National Cancer Institute's definition doesn't clarify whether personalized medicine targets individuals or subpopulations. When examining widely used examples of personalized medicine, such as the HER2-trastuzumab application, we observe that a specific subset of women with early breast cancer possesses HER2-positive tumors, making them eligible for trastuzumab treatment, which is effective for this tumor type. Nevertheless, since all individuals within this subgroup receive trastuzumab in the same manner (e.g., identical dosage regimens), many perceive it as an instance of subgroup or stratified medicine<sup>66</sup>.

The President's Council recognizes this and further asserts that this type of medicine can still be categorized as personalized medicine. Consequently, purists might argue that the majority of current instances of personalized medicine



aren't genuinely personalized. Depending on one's perspective, it's possible to assert either that personalized medicine hasn't fully arrived or to embrace a broader definition of personalized medicine and assert its existence. The definitions outlined above cater to both perspectives since they do not explicitly differentiate between personalized and stratified medicine.

### Is personalized medicine the future of healthcare

Yes, personalized medicine is widely recognized as a pivotal component of the future of healthcare<sup>67</sup>. It represents a paradigm shift towards tailoring medical treatments and interventions to the individual characteristics of each patient. This approach acknowledges the unique genetic makeup, lifestyle factors, and environmental influences that contribute to an individual's health and disease susceptibility.

Numerous experts, researchers, and healthcare professionals have highlighted the transformative potential of personalized medicine in improving patient outcomes, enhancing preventive measures, and optimizing therapeutic strategies<sup>68</sup>. As technology continues to advance, particularly in fields such as genomics, proteomics, and data analytics, the integration of personalized medicine into mainstream healthcare practices is expected to expand.

While challenges such as ethical considerations, disparities in access, and regulatory frameworks exist, the overall trajectory suggests that personalized medicine will continue to play an increasingly significant role in shaping the future of healthcare<sup>69</sup>.

### CONCLUSION

Personalized medicine signifies a significant

shift in healthcare, offering customized treatments based on individual genetic, lifestyle and disease factors. This approach holds great potential for enhancing patient outcomes, minimizing adverse reactions, and revolutionizing medical care. By tailoring therapies to specific patient groups and genetic indicators, personalized medicine not only improves treatment effectiveness but also promotes a proactive and preventative healthcare approach<sup>70,71</sup>.

Furthermore, personalized medicine fosters innovation in drug development, diagnostics, and healthcare delivery, leading to more efficient and impactful medical interventions. While initial challenges and costs may arise with implementation<sup>68,72</sup>. The long-term benefits of personalized medicine are substantial, including heightened patient satisfaction, reduced healthcare expenses, and advancements in medical research.

Ultimately, personalized medicine represents the future of healthcare. In the future, envisioning a personalized approach, individuals may receive their complete genomic information at birth, integrated into individual medical records. This data would empower physicians and clinicians to tailor more effective healthcare strategies based on individuals' predispositions to various diseases.

### ACKNOWLEDGEMENT

The authors would like to thank AKS University, Satna, M.P. For motivating in publication of this work in a Reputed Journal.

### Conflict of interest

The authors have no conflicts of interest.

### REFERENCES

1. Vogenberg FR.; Barash C Isaacson and Pursel M: *Personalized medicine: Part 1: Evolution and development into theranostics*. P T., **2010**, *35*, 560–576.
2. Vogenberg FR.; Barash CI and Pursel M: *Personalized medicine: Part 2: Ethical, legal, and regulatory issues*. P T, **2010**, *35*, 624–642
3. Sadée W and Dai Z: *Pharmacogenetics/genomics and personalized medicine.*, *Hum Mol Genet.*, **2005**, *14*, R207–R214.
4. Tezak Z, Kondratovich MV and Mansfield E: US FDA and personalized medicine: In vitro diagnostic regulatory perspective., *Per Med.*, **2010**, *7*, 517–530.
5. U.S. National Library of Medicine, **2021**, Precision Medicine. Retrieved from <https://ghr.nlm.nih.gov/primer/precisionmedicine/definition>.
6. Precision Medicine in Oncology: *New Practice Models and Roles for Oncology Nurses.*" *Seminars in Oncology Nursing.*, **2018**, *34*(2), 155-160.

7. Personalized Medicine in Type 2 Diabetes." *Clinical Therapeutics.*, **2019**, *41*(9), 1620-1631
8. Personalized Medicine in Cardiology." *Mayo Clinic Proceedings.*, **2019**, *94*(10), 1942-1953
9. National Human Genome Research Institute (NHGRI), **2021**, Precision Medicine. Retrieved from <https://www.genome.gov/precision-medicine>
10. <https://www.genome.gov/genetics-glossary/Personalized-Medicine>
11. Shah GL.; Majhail N.; Khera N.; Giralt S. Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities., *Curr Hematol Malig Rep.*, **2018** doi: 10.1007/s11899-018-0444-z
12. National Institutes of Health, **2020**, Precision Medicine Initiative. Retrieved from <https://www.nih.gov/precision-medicine-initiative-cohort-program>
13. The Promise of Personalized Medicine." *Journal of the American Medical Association.*, **2018**, *319*(9), 853-854.
14. Personalized Medicine in Oncology: Genomic Testing and Treatment Recommendations." *American Society of Clinical Oncology Educational Book.*, **2019**, *39*, e204-e214.
15. The Role of Personalized Medicine in Disease Prevention and Detection." *Annual Review of Medicine.*, **2020**, *71*, 27-37.
16. Monitoring and Adjusting Treatment in Personalized Medicine: Time to Abandon One-Size-Fits-All Approach?" *Frontiers in Genetics.*, **2019**, *10*, 1117.
17. Personalized Medicine: Tailoring Treatment to the Individual Patient." Harvard Health Publishing, Harvard Medical School.
18. [www.Age of Personalized Medicine.org](http://www.AgeofPersonalizedMedicine.org)
19. Vogenberg FR, Barash C Isaacson and Pursel M: Personalized medicine: Part 1: Evolution and development into theranostics. *P T.*, **2010**, *35*, 560–576.
20. Vogenberg FR.; Barash CI and Pursel M: Personalized medicine: Part 2: Ethical, legal, and regulatory issues. *P T.*, **2010**, *35*, 624–642.
21. Hamburg MA and Collins FS., *N Engl J Med.*, **2010**, *363*, 301–304.
22. Sairamesh J and Rossbach M: An economic perspective on personalized medicine., *HUGO J.*, **2013**, *7*, 1.
23. Association of the British Pharmaceutical Industry: The stratification of disease for personalised medicines.<http://www.abpi.org.uk/our-work/library/medical-disease/Pages/personalised-medicines.aspx> April 16–**2009**
24. Privacy and Security in the Era of Digital Health: What Should translational researchers know and do about it?" *American Journal of Translational Research.*, **2019**, *11*(6), 3235-3242.
25. The cost-effectiveness of personalized medicine: from access to outcomes." *Journal of Personalized Medicine.*, **2020**, *10*(1), 28.
26. Ethical issues in personalized medicine: A systematic literature review." *European Journal of Human Genetics.*, **2019**, *27*, 1065-1077.
27. Regulatory challenges in personalized medicine." *Journal of Personalized Medicine.*, **2018**, *8*(1), 3.
28. Interdisciplinary collaboration in personalized medicine: the case of the Luxembourg Personalized Medicine Consortium." *Journal of Translational Medicine.*, **2018**, *16*, 300.
29. Ethical, social, and regulatory considerations in the implementation of precision medicine." *Personalized Medicine.*, **2018**, *15*(2), 109-115
30. Data interpretation in personalized medicine: Current applications and future perspectives." *Methods.*, **2020**, *188*, 41-49.
31. FDA takes steps to provide clarity on developing new drug products in the age of individualized medicine. January 4, 2021. [www.fda.gov/news-events/press-announcements/fda-takes-steps-provide-clarity-developing-new-drug-products-age-individualized-medicine](http://www.fda.gov/news-events/press-announcements/fda-takes-steps-provide-clarity-developing-new-drug-products-age-individualized-medicine). Accessed November 29, **2022**.
32. Personalized Medicine: Tailoring Treatment to the Individual Patient." Harvard Health Publishing, Harvard Medical School.
33. Raghu, G., & Sarma, G. R., Precision Medicine: An Overview., *Current Research in Pharmacology and Drug Discovery.*, **2017**, *1*(1), 1-3. doi: 10.19080/CRPTOJ.2017.01.555556.
34. FDA Focus area: individualized therapeutics and precision medicine. September 6, 2022. [www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-individualized-therapeutics-and-precision-medicine](http://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-individualized-therapeutics-and-precision-medicine). Accessed November 29, **2022**.

35. FDA IND submissions for individualized antisense oligonucleotide drug products: administrative and procedural recommendations guidance for sponsor-investigators. January 2021. [www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural). Accessed November 29, **2022**.
36. Pirmohamed, M., & Hughes, D. A., *The pharmacogenomics Journal.*, **2018**, *18*(2), 203–207.
37. Schilsky, R. L., Personalized medicine in oncology: the future is now., *Nature Reviews Drug Discovery.*, **2010**, *9*(5), 363–366.
38. Phillips, K. A.; Veenstra, D. L., & Oren, E., Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review., *JAMA.*, **2008**, *299*(23), 2736–2744.
39. Waters, L., & Gazzard, B., The role of antiretroviral therapy in the management of HIV infection., *Clinical Medicine.*, **2013**, *13*(5), 457–460 <https://doi.org/10.7861/clinmedicine.13-5-457>.
40. Schwarz, J. M.; Rodelsperger, C.; Schuelke, M., & Seelow, D., MutationTaster evaluates disease-causing potential of sequence alterations., *Nature Methods.*, **2010**, *7*(8), 575–576.
41. Khera, A. V.; Chaffin, M.; Aragam, K. G.; Haas, M. E.; Roselli, C.; Choi, S. H., ... & Kathiresan, S., *Nature Genetics.*, **2018**, *50*(9), 1219–1224.
42. Le Tourneau, C.; Delord, J. P.; Gonçalves, A.; Gavaille, C.; Dubot, C.; Isambert, N.,... & Massard, C., *The Lancet Oncology.*, **2015**, *16*(13), 1324–1334.
43. Hall-Flavin, D. K.; Winner, J. G.; Allen, J. D.; Jordan, J. J.; Nesheim, R. S.; Snyder, K. A.,... & Mrazek, D. A., *Translational Psychiatry.*, **2013**, *3*(9), e287
44. Wilsdon T.; Barron A.; Edwards G.; Lawlor R.; Report of the benefits of personalised medicine to patients, society and health care system, European biopharmaceutical Enterprises (EBE) and European Federation of pharmaceutical industries and Associations (EFPIA)., **2018**.
45. Hamburg, M. A., & Collins, F. S., *New England Journal of Medicine.*, **2010**, *363*(4), 301–304.
46. Ku, C. S.; Loy, E. Y.; Salim, A.; Pawitan, Y., & Chia, K. S., *Journal of Human Genetics.*, **2010**, *55*(7), 403–415.
47. Collins, F. S., & Varmus, H., A new initiative on precision medicine., *New England Journal of Medicine.*, **2015**, *372*(9), 793–795.
48. Hamburg, M. A., & Collins, F. S., The path to personalized medicine., *New England Journal of Medicine.*, **2010**, *363*(4), 301–304.
49. Crews, K. R.; Hicks, J. K.; Pui, C. H.; Relling, M. V., & Evans, W. E., *Pharmacogenomics and individualized medicine: Translating science into practice. Clinical Pharmacology & Therapeutics.*, **2012**, *92*(4), 467–475.
50. Manolio, T. A.; Chisholm, R. L.; Ozenberger, B.; Roden, D. M.; Williams, M. S.; Wilson, R.; & Bick, D., Implementing genomic medicine in the clinic: The future is here., *Genetics in Medicine.*, **2013**, *15*(4), 258–267.
51. Garrison, L. P., & Towse, A., *Journal of Personalized Medicine.*, **2010**, *1*(2), 109–132.
52. Schilsky, R. L., Personalized medicine in oncology: The future is now., *Nature Reviews Drug Discovery.*, **2010**, *9*(5), 363–366.
53. Patel, J. N., & Steiner, T. J., *Journal of Personalized Medicine.*, **2015**, *5*(1), 40–53.
54. Haga, S. B., Barry, W. T., Mills, R., Svetkey, L., Suchindran, S., Willard, H. F., & Ginsburg, G. S., Impact of delivery models on understanding genomic risk for type 2 diabetes., *Public Health Genomics.*, **2014**, *17*(2), 95–104.
55. Manolio, T. A.; Chisholm, R. L.; Ozenberger, B.; Roden, D. M.; Williams, M. S.; Wilson, R.; & Bick, D., Implementing genomic medicine in the clinic: The future is here., *Genetics in Medicine.*, **2013**, *15*(4), 258–267.
56. Schleidgen, S.; Klingler, C.; Bertram, T.; Rogowski, W. H., & Marckmann, G., What is personalized medicine: Sharpening a vague term based on a systematic literature review., *BMC Medical Ethics.*, **2013**, *14*(1), 55.
57. Association of the British Pharmaceutical Industry: The stratification of disease for personalized medicines. <http://www.abpi.org.uk/our-work/library/medical-disease/Pages/personalised-medicines.aspx> April 16–**2009**.
58. Morse, G. D.; Wu, B., & Zhang, L., *Journal of the American Pharmacists Association.*, **2014**, *54*(5), e304–e315.
59. Cohen, L. S.; Sciascia, T.; Saccomano, S. J., & Batra, V., *American Journal of Health-System Pharmacy.*, **2016**, *73*(7), 455–463.

60. Ozawa, S.; Evans, J. P.; Kirchoff, K. T., & Larson, E. B., Pharmacogenomic testing: A systematic review of the economic evidence for its effectiveness on patient outcomes., *Personalized Medicine.*, **2018**, *15*(3), 245–257.
61. Cohen, L. S.; Sciascia, T.; Saccomano, S. J., & Batra, V., *American Journal of Health-System Pharmacy.*, **2016**, *73*(7), 455-463.
62. Vogenberg, F. R., & Isaacson Barash, C., *The American Journal of Managed Care.*, **2010**, *16*(4), e91-e95.
63. Santos, P.; Batalha, L. R.; Dinis-Oliveira, R. J., & Magalhães, T., Pharmacogenomics in pharmacy practice: Current perspectives. *Integrated Pharmacy Research & Practice.*, **2020**, *9*, 123–131.
64. Elewa H.; Awaisu A. Pharmacogenomics in pharmacy practice: current perspectives., *Integr Pharm Res Pract.*, **2019**, *11*(8), 97-104.
65. ASHP statement on the pharmacist's role in clinical pharmacogenomics., *Am J Health Syst Pharm.*, **2015**, *72*(7), 579-581.
66. Trusheim MR.; Berndt ER.; Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers., *Nat Rev Drug Discover.*, **2007**, *6*, 287-93.
67. Collins, F. S., & Varmus, H., *New England Journal of Medicine.*, **2015**, *372*(9), 793-795.
68. Hamburg, M. A., & Collins, F. S., *New England Journal of Medicine.*, **2010**, *363*(4), 301-304.
69. Jameson, J. L., & Longo, D. L., *New England J. of Medicine.*, **2015**, *372*(23), 2229-2234.
70. Khoury, M. J., Iademarco, M. F., & Riley, W. T., *American Journal of Preventive Medicine.*, **2016**, *50*(3), 398-401.
71. Mirnezami, R., Nicholson, J., & Darzi, A., *New England Journal of Medicine.*, **2021**, *366*(6), 489-491.
72. Ginsburg, G. S., & Phillips, K. A., *Precision medicine: from science to value. Health Affairs.*, **2018**, *37*(5), 694-701.